SCHEMBL3209486

SCHEMBL3209486

Cc1ccc(NC(=O)Nc2cccc(CN3CCN4C(=O)OC(C)(C)[C@@H]4C3)c2F)cn1

nearest known ligand 0.39

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MTOR P42345 6/20 0.39
PIK3R1 P27986 4/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
SIRT2 Q8IXJ6 2/20 0.38
MAPK8 P45983 4/20 0.38
MAPK10 P53779 4/20 0.38
RORC P51449 2/20 0.37
DHODH Q02127 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
CCR3 P51677 4/20 0.35
MAPK9 P45984 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3198718 1.00 MTOR (0.39) MTORPIK3R1NPC1RAB9ASMN1; SMN2
SCHEMBL3198756 0.84 SIRT2 (0.40) MTORPIK3R1NPC1RAB9ASMN1; SMN2
SCHEMBL3198667 0.84 SIRT2 (0.40) MTORPIK3R1NPC1RAB9ASMN1; SMN2
SCHEMBL3196716 0.83 NPC1 (0.53) NPC1RAB9ASMN1; SMN2MAPK8MAPK10
SCHEMBL3206122 0.82 MTOR (0.38) MTORPIK3R1MAPK8MAPK10NPSR1
SCHEMBL3200917 0.82 MTOR (0.38) MTORPIK3R1MAPK8MAPK10NPSR1
SCHEMBL8272218 0.80 NPC1 (0.45) NPC1RAB9ASMN1; SMN2MAPK8MAPK10
SCHEMBL3198122 0.80 NPC1 (0.49) NPC1RAB9ASMN1; SMN2MAPK8MAPK10
SCHEMBL3196777 0.79 RORC (0.41) NPC1RAB9ASMN1; SMN2SIRT2MAPK8
SCHEMBL3214394 0.79 RORC (0.47) NPC1RAB9ASMN1; SMN2MAPK8MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 US claimed
US-8871768-B2 Certain chemical entities, compositions and methods CYTOKINETICS, INC. (US) 2014-10-28 US disclosed
US-20130324549-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INC. (US) 2013-12-05 US disclosed
US-8445495-B2 Certain Chemical entities, compositions and methods CYTOKINETICS, INC. (US) 2013-05-21 US disclosed
EP-1959960-B1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS INC (US) 2013-04-10 EP disclosed
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2010-02-04 US disclosed
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161617-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 MTOR 1762/4885PIK3R1 4057/4885NPC1 4691/4885
US-20130324549-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS TNNI3, TNNT2, MYLK2 MTOR 1762/4885PIK3R1 4057/4885NPC1 4691/4885
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods TNNI3, TNNT2, MYLK2 MTOR 1762/4885PIK3R1 4057/4885NPC1 4691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.